SVCM
Saturn V Capital Management Portfolio holdings
AUM
$247M
This Quarter Return
+11.46%
1 Year Return
+2.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$247M
AUM Growth
+$247M
(+25%)
Cap. Flow
+$28.4M
Cap. Flow
% of AUM
11.52%
Top 10 Holdings %
Top 10 Hldgs %
69.44%
Holding
26
New
5
Increased
10
Reduced
9
Closed
2
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$22M |
| 2 |
Dyne Therapeutics
DYN
|
$13.9M |
| 3 |
Vaxcyte
PCVX
|
$10.1M |
| 4 |
LENZ
LENZ Therapeutics
LENZ
|
$10M |
| 5 |
Neurocrine Biosciences
NBIX
|
$7.31M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$27.8M |
| 2 |
Disc Medicine
IRON
|
$6.46M |
| 3 |
Merus
MRUS
|
$5.2M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$5.06M |
| 5 |
SLN
Silence Therapeutics
SLN
|
$4.05M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Jazz Pharmaceuticals
JAZZ
$7.75B
| $22M | 8.9% |
+206,952
| New | +$22M |
|
|
2
Disc Medicine
IRON
$2.07B
| $21M | 8.5% |
396,115
-122,062
| -24% | -$6.46M |
|
3
Amylyx Pharmaceuticals
AMLX
$836M
| $20.9M | 8.47% |
3,260,570
+834,134
| +34% | +$5.35M |
|
|
4
Vaxcyte
PCVX
$4B
| $17.7M | 7.17% |
544,221
+311,926
| +134% | +$10.1M |
|
5
Cogent Biosciences
COGT
$1.69B
| $16.5M | 6.69% |
2,297,524
+817,504
| +55% | +$5.87M |
|
6
Celcuity
CELC
$2.17B
| $15.8M | 6.41% |
1,185,520
+91,843
| +8% | +$1.23M |
|
7
CG Oncology
CGON
$2.04B
| $15.3M | 6.18% |
586,647
+8,951
| +2% | +$233K |
|
8
Xenon Pharmaceuticals
XENE
$2.98B
| $14.7M | 5.94% |
468,364
+54,653
| +13% | +$1.71M |
|
|
9
Dyne Therapeutics
DYN
$1.92B
| $13.9M | 5.62% |
+1,455,429
| New | +$13.9M |
|
10
MoonLake Immunotherapeutics
MLTX
$3.54B
| $13.7M | 5.56% |
290,784
-53,065
| -15% | -$2.5M |
|
|
11
Merus
MRUS
$4.98B
| $11.8M | 4.78% |
224,260
-98,951
| -31% | -$5.2M |
|
|
CNTA
12
Centessa Pharmaceuticals
CNTA
$2.25B
| $10.4M | 4.22% |
793,327
+344,635
| +77% | +$4.53M |
|
|
LENZ
13
LENZ Therapeutics
LENZ
$1.1B
| $10M | 4.07% |
+342,312
| New | +$10M |
|
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $7.31M | 2.96% |
+58,181
| New | +$7.31M |
|
15
Ocular Therapeutix
OCUL
$2.12B
| $6.76M | 2.74% |
728,576
+130,385
| +22% | +$1.21M |
|
|
16
Ascendis Pharma
ASND
$11.8B
| $6.59M | 2.67% |
38,191
-161,073
| -81% | -$27.8M |
|
17
argenx
ARGX
$43.6B
| $5.67M | 2.3% |
10,285
-3,577
| -26% | -$1.97M |
|
|
ABVX
18
Abivax
ABVX
$6.12B
| $4.76M | 1.93% |
622,479
+69,553
| +13% | +$532K |
|
|
19
Syndax Pharmaceuticals
SNDX
$1.41B
| $4.69M | 1.9% |
500,551
-540,729
| -52% | -$5.06M |
|
20
NewAmsterdam Pharma
NAMS
$2.71B
| $4M | 1.62% |
220,695
+104,342
| +90% | +$1.89M |
|
|
CTNM
21
Contineum Therapeutics
CTNM
$293M
| $1.27M | 0.51% |
319,348
-241,631
| -43% | -$959K |
|
22
Replimune Group
REPL
$422M
| $1.2M | 0.49% |
+128,917
| New | +$1.2M |
|
23
KalVista Pharmaceuticals
KALV
$678M
| $710K | 0.29% |
62,793
-192,267
| -75% | -$2.17M |
|
|
SLN
24
Silence Therapeutics
SLN
$227M
| $201K | 0.08% |
34,737
-697,726
| -95% | -$4.05M |
|
25
Crinetics Pharmaceuticals
CRNX
$2.92B
| – | – |
-59,017
| Closed | -$1.98M |
|